title: Viral hepatitis in liver transplantation.
abstract: Liver transplantation is the only alternative for patients with end-stage liver disease. Viral hepatitis B and C are among the most common causes of cirrhosis and hepatocellular carcinoma and a frequent indication for liver transplantation. Hepatitis B virus immunoglobulin and nucleot(s)ide analogues have facilitated the management of patients with hepatitis B who have received liver transplants and resulted in excellent long-term outcomes. On the contrary, recurrence of hepatitis C is the main cause of graft loss in most transplant programs. Current therapeutic approaches are far from optimal, because sustained virologic responses are only achieved in one-third of treated patients, and adverse effects are common and severe. However, the rapid development of direct-acting antivirals against hepatitis C virus will change the management of this disease and in a few years prevent graft infection with this virus.
authors.affiliation: Liver Unit, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Crespo
authors.forename: Zoe
authors.initials: Z
authors.lastname: Mariño
authors.forename: Miquel
authors.initials: M
authors.lastname: Navasa
authors.forename: Xavier
authors.initials: X
authors.lastname: Forns
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D058625:End Stage Liver Disease / Q000378:metabolism / Q000601:surgery* / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000150:complications / Q000517:prevention & control* / Q000601:surgery*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000517:prevention & control* / Q000601:surgery*; D006801:Humans; D016031:Liver Transplantation; D012008:Recurrence; D055502:Secondary Prevention / Q000379:methods
chemical_list: D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens